Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer	Solid Tumors	Not yet recruiting	Phase 2	2025-01-07		NCT06762327

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nanjing First Hospital, Nanjing Medical University	96

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials